CD20 Expression in B-cell Lymphomas and Its Predictive Significance
Author Information
Author(s): Veronika Kloboves Prevodnik, Jaka Lavrenčak, Mateja Horvat, Barbara Jezeršek Novaković
Primary Institution: Institute of Oncology, Ljubljana, Slovenia
Hypothesis
The study aims to quantify CD20 expression in B-cell lymphomas to determine the proportion of patients with low CD20 expression who may not benefit from rituximab treatment.
Conclusion
Approximately 25% of B-cell lymphoma patients have CD20 expression below the cut-off value, indicating that low CD20 expression might be more common than previously thought.
Supporting Evidence
- 17.5% of patients in a previous study had low CD20 expression.
- CD20 expression was significantly lower in chronic lymphocytic leukemia compared to other B-cell lymphomas.
- 24.3% of patients in this study had CD20 expression below the cut-off value.
Takeaway
This study found that many patients with B-cell lymphoma have low levels of a protein called CD20, which can affect how well they respond to a common treatment.
Methodology
Cytological samples from 218 patients were analyzed for CD20 expression using flow cytometry.
Limitations
The study's findings may not be representative due to the small number of patients in some lymphoma groups.
Participant Demographics
Patients diagnosed with primary or recurrent lymphoma at the Institute of Oncology Ljubljana, Slovenia.
Statistical Information
P-Value
0.002
Statistical Significance
p = 0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website